# Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)

> **NCT06643117** · PHASE3 · TERMINATED · sponsor: **Formycon AG** · enrollment: 25 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** FYB206
- **BIOLOGICAL:** FYB206
- **BIOLOGICAL:** Keytruda

## Key facts

- **NCT ID:** NCT06643117
- **Lead sponsor:** Formycon AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-10-03
- **Primary completion:** 2025-05-13
- **Final completion:** 2025-05-13
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Formycon concluded that continuing the trial is no longer necessary for the development and approval of FYB206. The therapeutic comparability of FYB206 to Keytruda can be demonstrated based on comprehensive analytical and PK comparability data
- **Last updated:** 2025-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06643117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06643117, "Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06643117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*